Dr. David Swoboda Promoted to Clinical Director of Leukemia Program at TGH Cancer Institute

Published: Dec 10, 2023

Dr. David Swoboda is a physician-scientist focusing on therapeutics for patients with acute leukemias and myelodysplastic syndromes (MDS).

Tampa, Fla. (Dec. 10, 2023)­ – Tampa General Hospital (TGH) Cancer Institute has promoted Dr. David Swoboda to the position of Clinical Director of Leukemia. In his new role, Swoboda will oversee the growth of a highly specialized team of physicians, advanced practice providers (APPs), pharmacists, nurse navigators and other supportive-care providers, focusing on the treatment of patients with acute leukemias and myelodysplastic syndromes (MDS), conditions that can occur when the blood-forming cells in the bone marrow become abnormal. Swoboda joined the Cancer Institute in 2021.

“I’m proud to be part of one of the country’s leading academic health systems and the teams of doctors and nurses who emphasize leading-edge cancer that also focuses on the needs of the whole patient,’’ Swoboda said. “The advancements we’re seeing in leukemia therapies are setting a precedent. We’re offering a level of care that many people might not be able to receive otherwise.’’

Swoboda is a hematologist oncologist, specializing in malignant hematology with particular focus in the study of leukemias, MDS, and myeloproliferative disorders. Myeloproliferative disorders are blood cancers caused by changes in the stem cells inside bone marrow, the tissue that produces blood cells.

Prior to joining Tampa General, he was a chief hematology-oncology fellow at Moffitt Cancer Center in Tampa after having served as a chief resident at MedStar Georgetown University Hospital in Washington, D.C. Swoboda received his medical degree from Florida State University College of Medicine in Tallahassee, where he was the president of the Internal Medicine Interest Group. He is a member of the American Society of Hematology, Society for Hematology Oncology, American Society of Clinical Oncology, and American College of Physicians.

Swoboda views practicing medicine as a highly personal endeavor. He enjoys developing a close relationship with his patients and their families, building trust and gaining a full understanding of each disease in order to provide comprehensive care tailored to each person.

“I’m thrilled that someone with the credentials of Dr. Swoboda, a highly productive and talented physician-scientist, is helping the TGH Cancer Institute lead the way in advanced treatments for leukemias,’’ said Dr. Eduardo M. Sotomayor, vice president and executive director of the TGH Cancer Institute. “This is another example of the level of our people, tools and approaches to helping patients heal.’’

Tampa General’s cancer physicians offer a highly coordinated range of multidisciplinary specialties such as hematologic malignancies, thoracic, breast, colorectal, gynecologic oncology, and bone marrow transplant and cell therapies. Advanced subspecialties include liver and hepatobiliary oncology, otolaryngology (ear, nose, and throat), and genitourinary (reproductive system and genitourinary tract). Tampa General takes a multidisciplinary approach and strongly emphasizes compassionate and personalized care that focuses on the whole patient. For more information about the Cancer Institute, visit www.tgh.org/cancer.